Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation

Professor Gregory Lip; Ahsan Ali Khan; Brian Olshansky

doi:10.1161/circulationaha.119.040021

Abstract

1 min read

TEST 02 - Elsevier's Scopus, the largest abstract and citation database of peer-reviewed literature. Search and access research from the science, technology, medicine, social sciences and arts and humanities fields.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Letter2021

Utilizing biomarkers in atrial fibrillation: the pros and cons

Wern Yew Ding, Garry McDowell, Professor Gregory Lip

Editorial Material2021

Atrial fibrillation in the presence of chronic kidney disease: Toablate or not to ablate

Wern Yew Ding, Dhiraj Gupta, Christopher F. Wong, Professor Gregory Lip

Letter2020

Understanding the global burden of atrial fibrillation and regional variations: we need improvement

Marco Vitolo, Professor Gregory Lip

Article2020

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres, Elena Arbelo, Jeroen J. Bax, Carina Blomström‐Lundqvist, Giuseppe Boriani, Manuel Castella, Polychronis Dilaveris, Jean‐Pierre Lebeau, Professor Gregory Lip, G. Neil Thomas, Isabelle C. Van Gelder, Bart P. van Putte, Caroline Watkins, Paulus Kirchhof, Michael Kühne, Victor Aboyans, Anders Ahlsson, Paweł Balsam, Johann Bauersachs,

Editorial Material2021

Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation

Stanley Nattel, Professor Gregory Lip, David Filgueiras‐Rama, Dobromir Dobrev